Skip to main content
Search

Zhengzhou University

5 related articles

Subscribe to updates
  1. Backdoor detection stops reading only the last layer: CLEAR fuses cross-layer extreme responses for 99.54% average TPR on Tiny-ImageNet

    CLEAR moves backdoor sample detection from single-layer activations to cross-layer extreme responses: batch normalization statistics align hidden-layer features to a common scale, each channel's spatial minimum becomes the anomaly representation, and particle swarm optimization searches layer weights. On CIFAR-10 and Tiny-ImageNet, CLEAR reaches average true positive rates of 97.54% and 99.54% with average false positive rates of 0.16% and 0.03%, above AC, SCALE-UP, AIBD and CCD; models retrained on its purified data stay close to benign accuracy.

  2. arXiv

    Remote sensing super-resolution stops feeding dense low-res maps: object slots lift PSNR by 2.03 dB over DiT4SR on UCMerced

    Remote sensing super-resolution previously injected low-resolution observations as dense spatial conditions into a diffusion Transformer, so small foreground objects were easily diluted by dominant backgrounds. MOSAIC organizes degraded observations into compact object-level and layout-level structural slots, fuses them across resolutions, and retrieves recurring structural priors from a shared prototype memory, then injects them into a frozen DiT4SR backbone through lightweight residual modulation. On UCMerced, AID and RSSCN7, PSNR is best at both scales, exceeding DiT4SR by 2.03 dB on UCMerced, 4.54 dB on AID and 1.49 dB on RSSCN7, with the lowest LPIPS on RSSCN7 and AID.

  3. Precision Management of Gastrointestinal Tumor-Associated Osteoporosis Driven by Cutting-Edge Technologies: Current Status, Challenges, and Future Prospects

    This review systematically evaluates the methodological quality, clinical validity, and translational evidence of cutting-edge technologies in the precision management of gastrointestinal tumor-associated osteoporosis (GTO), summarizing their current applications in AI-assisted early screening and risk prediction, nano-enabled targeted bone protection, and multiomics-based exploration of the tumor-bone-gut axis, and discussing barriers to clinical translation such as limited AI generalizability, nanomedicine safety and manufacturing challenges, difficulties in multidimensional data integration and standardization, imperfect multidisciplinary collaboration, and ethical concerns, concluding that these technologies are expected to move GTO management from empirical practice toward precision m

  4. Clinical Implementation and Evaluation of an Artificial Intelligence-Driven One-Click Automatic Planning System for Functional Lung Avoidance Radiotherapy

    This study implemented AP-FLART, which integrates dosimetric score-based beam angle selection, multi-modality-guided dose prediction, and function-guided dose mimicking, within RayStation and evaluated it on a test dataset of 33 lung cancer patients who underwent SPECT ventilation or perfusion imaging and lung radiotherapy, finding that automatic FLART plans significantly reduced high-function lung mean dose by 15.1% versus manual conventional radiotherapy plans, lowered the probability of grade >=2 radiation pneumonitis by 6.25 percentage points (27%) among FLART-benefiting patients, achieved clinical benefits similar to manual FLART plans, were clinically acceptable without modification in 87.9% of cases, and cut planning time from 2-3 hours to approximately 8 minutes.

  5. Multimodal AI and single-cell transcriptomics integrate to construct a histopathological prognostic model for bladder cancer, revealing the RTN3-glycolysis axis in chemoresistance

    This study integrated six public single-cell RNA sequencing datasets, used inferCNV to infer copy number variations at the single-cell level and identify a high-CNV (HCNV) malignant subpopulation, built a multimodal deep-learning AI prognostic model on routine H&E-stained sections with HCNV activity as the biological anchor for pathology feature selection, and through multiomics screening plus in vitro and in vivo experiments identified RTN3 as the core driver gene, showing that RTN3 activates JAK2/STAT3 to transcriptionally upregulate glycolytic enzymes PKM2, GLUT1 and LDHA, driving glycolytic metabolic reprogramming and conferring gemcitabine resistance in bladder cancer.

You’re all caught up